Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio

James D. Alderman, Richard C. Pasternak, Frank M. Sacks, Harton S. Smith, E. Scott Monrad, William Grossman

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

One hundred one patients with coronary artery disease and pretreatment ratios of total cholesterol to high density lipoprotein (HDL) cholesterol >4.0 were treated with niacin, commencing at low dosages (100 to 250 mg twice daily) and gradually increasing the dosage over 4 to 8 weeks to 1,000 mg twice daily. Dosage adjustments were made to minimize side effects. At a mean follow-up duration of 11 ± 7 months, and a mean dosage of 1,415 ± 698 mg/day, the group had a 13% reduction in total cholesterol, 31% increase in HDL and 32% decrease in the cholesterol to HDL ratio. A subgroup of 62 patients taking >1,000 mg/day of niacin had an 18% reduction in total cholesterol, 32% increase in HDL and 36% improvement in the cholesterol to HDL ratio. A subgroup of 39 patients taking <1,000 mg/day of niacin had only a 5% reduction in total cholesterol, although a 29% increase in HDL and a 24% decrease in the cholesterol to HDL ratio were recorded. Side effects of niacin were reported in 38% of the patients, but led to discontinuation of therapy in only 4. Niacin can be administered in a fashion that is well tolerated, inexpensive and very effective in improving the cholesterol to HDL ratio.

Original languageEnglish (US)
Pages (from-to)725-729
Number of pages5
JournalThe American Journal of Cardiology
Volume64
Issue number12
DOIs
StatePublished - Oct 1 1989
Externally publishedYes

Fingerprint

Niacin
HDL Cholesterol
Cholesterol
HDL Lipoproteins
Serum
Coronary Artery Disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. / Alderman, James D.; Pasternak, Richard C.; Sacks, Frank M.; Smith, Harton S.; Monrad, E. Scott; Grossman, William.

In: The American Journal of Cardiology, Vol. 64, No. 12, 01.10.1989, p. 725-729.

Research output: Contribution to journalArticle

@article{d0166fbebd354addb44e47f8491a9a45,
title = "Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio",
abstract = "One hundred one patients with coronary artery disease and pretreatment ratios of total cholesterol to high density lipoprotein (HDL) cholesterol >4.0 were treated with niacin, commencing at low dosages (100 to 250 mg twice daily) and gradually increasing the dosage over 4 to 8 weeks to 1,000 mg twice daily. Dosage adjustments were made to minimize side effects. At a mean follow-up duration of 11 ± 7 months, and a mean dosage of 1,415 ± 698 mg/day, the group had a 13{\%} reduction in total cholesterol, 31{\%} increase in HDL and 32{\%} decrease in the cholesterol to HDL ratio. A subgroup of 62 patients taking >1,000 mg/day of niacin had an 18{\%} reduction in total cholesterol, 32{\%} increase in HDL and 36{\%} improvement in the cholesterol to HDL ratio. A subgroup of 39 patients taking <1,000 mg/day of niacin had only a 5{\%} reduction in total cholesterol, although a 29{\%} increase in HDL and a 24{\%} decrease in the cholesterol to HDL ratio were recorded. Side effects of niacin were reported in 38{\%} of the patients, but led to discontinuation of therapy in only 4. Niacin can be administered in a fashion that is well tolerated, inexpensive and very effective in improving the cholesterol to HDL ratio.",
author = "Alderman, {James D.} and Pasternak, {Richard C.} and Sacks, {Frank M.} and Smith, {Harton S.} and Monrad, {E. Scott} and William Grossman",
year = "1989",
month = "10",
day = "1",
doi = "10.1016/0002-9149(89)90754-6",
language = "English (US)",
volume = "64",
pages = "725--729",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio

AU - Alderman, James D.

AU - Pasternak, Richard C.

AU - Sacks, Frank M.

AU - Smith, Harton S.

AU - Monrad, E. Scott

AU - Grossman, William

PY - 1989/10/1

Y1 - 1989/10/1

N2 - One hundred one patients with coronary artery disease and pretreatment ratios of total cholesterol to high density lipoprotein (HDL) cholesterol >4.0 were treated with niacin, commencing at low dosages (100 to 250 mg twice daily) and gradually increasing the dosage over 4 to 8 weeks to 1,000 mg twice daily. Dosage adjustments were made to minimize side effects. At a mean follow-up duration of 11 ± 7 months, and a mean dosage of 1,415 ± 698 mg/day, the group had a 13% reduction in total cholesterol, 31% increase in HDL and 32% decrease in the cholesterol to HDL ratio. A subgroup of 62 patients taking >1,000 mg/day of niacin had an 18% reduction in total cholesterol, 32% increase in HDL and 36% improvement in the cholesterol to HDL ratio. A subgroup of 39 patients taking <1,000 mg/day of niacin had only a 5% reduction in total cholesterol, although a 29% increase in HDL and a 24% decrease in the cholesterol to HDL ratio were recorded. Side effects of niacin were reported in 38% of the patients, but led to discontinuation of therapy in only 4. Niacin can be administered in a fashion that is well tolerated, inexpensive and very effective in improving the cholesterol to HDL ratio.

AB - One hundred one patients with coronary artery disease and pretreatment ratios of total cholesterol to high density lipoprotein (HDL) cholesterol >4.0 were treated with niacin, commencing at low dosages (100 to 250 mg twice daily) and gradually increasing the dosage over 4 to 8 weeks to 1,000 mg twice daily. Dosage adjustments were made to minimize side effects. At a mean follow-up duration of 11 ± 7 months, and a mean dosage of 1,415 ± 698 mg/day, the group had a 13% reduction in total cholesterol, 31% increase in HDL and 32% decrease in the cholesterol to HDL ratio. A subgroup of 62 patients taking >1,000 mg/day of niacin had an 18% reduction in total cholesterol, 32% increase in HDL and 36% improvement in the cholesterol to HDL ratio. A subgroup of 39 patients taking <1,000 mg/day of niacin had only a 5% reduction in total cholesterol, although a 29% increase in HDL and a 24% decrease in the cholesterol to HDL ratio were recorded. Side effects of niacin were reported in 38% of the patients, but led to discontinuation of therapy in only 4. Niacin can be administered in a fashion that is well tolerated, inexpensive and very effective in improving the cholesterol to HDL ratio.

UR - http://www.scopus.com/inward/record.url?scp=0024435086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024435086&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(89)90754-6

DO - 10.1016/0002-9149(89)90754-6

M3 - Article

C2 - 2801522

AN - SCOPUS:0024435086

VL - 64

SP - 725

EP - 729

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 12

ER -